公开(公告)号：US20220220157A1

公开(公告)日：2022-07-14

申请号：US17583511

申请日：2022-01-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefano COLLOCA ,  Riccardo CORTESE ,  Fabiana GRAZIOLI ,  Alfredo NICOSIA ,  Alessandra VITELLI

IPC: C07K14/005 ,  C12N15/86 ,  C07K14/075 ,  C07K14/75 ,  A61K39/12 ,  C12N15/861 ,  A61K39/155 ,  A61K39/21 ,  C12N7/00

Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

公开(公告)号：US20220112245A2

公开(公告)日：2022-04-14

申请号：US16467569

申请日：2017-12-08

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefano COLLOCA ,  Alessandra VITELLI ,  Benjamin WIZEL

IPC: C07K14/005 ,  A61K39/39 ,  A61K39/205 ,  C12N15/86 ,  A61P31/14 ,  A61K39/21 ,  A61P31/18 ,  A61K39/12

Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

公开(公告)号：US20170143820A1

公开(公告)日：2017-05-25

申请号：US15318490

申请日：2015-06-12

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ann-Muriel STEFF ,  Jean-Francois TOUSSAINT ,  Alessandra VITELLI

IPC: A61K39/155

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K39/235 ,  A61K2039/5256 ,  A61K2039/545 ,  C12N2710/10343 ,  C12N2760/18534

Abstract: Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.

公开(公告)号：US20230158134A1

公开(公告)日：2023-05-25

申请号：US18075064

申请日：2022-12-05

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefano COLLOCA ,  Alessandra VITELLI ,  Benjamin WIZEL

IPC: A61K39/12 ,  A61K39/205 ,  C07K14/005 ,  C12N15/86 ,  A61K39/235 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K39/205 ,  C07K14/005 ,  C12N15/86 ,  A61K39/235 ,  C12N7/00 ,  A61P31/14

Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

公开(公告)号：US20210069322A1

公开(公告)日：2021-03-11

申请号：US16772203

申请日：2018-12-14

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Babak BAYAT ,  Clarisse LORIN ,  Ventzislav Bojidarov VASSILEV ,  Alessandra VITELLI

IPC: A61K39/29 ,  C12N15/86 ,  C07K14/02 ,  A61P31/20

Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

公开(公告)号：US20210060150A1

公开(公告)日：2021-03-04

申请号：US16986413

申请日：2020-08-06

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefano COLLOCA ,  Virginia AMMENDOLA ,  Fabiana GRAZIOLI ,  Alessandra VITELLI ,  Alfredo NICOSIA ,  Riccardo CORTESE

IPC: A61K39/04 ,  C12N15/86 ,  A61K39/12 ,  C12N7/00 ,  A61P31/06 ,  A61K35/761 ,  C07K14/005 ,  C07K14/35 ,  A61K9/00 ,  A61K39/39 ,  A61K45/00 ,  C12N15/85

Abstract: There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.

公开(公告)号：US20230390381A1

公开(公告)日：2023-12-07

申请号：US18082456

申请日：2022-12-15

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ann-Muriel STEFF ,  Jean-Francois TOUSSAINT ,  Alessandra VITELLI

IPC: A61K39/155 ,  A61K39/235 ,  A61K39/12

CPC classification number: A61K39/155 ,  A61K39/235 ,  A61K39/12 ,  A61K2039/5256

Abstract: This disclosure provides immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent, e.g., co-localized, administration. More specifically, the respiratory pathogen is respiratory syncytial virus (RSV). This disclosure also concerns provides the use of such immunogenic combinations, and methods for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.

公开(公告)号：US20220305120A1

公开(公告)日：2022-09-29

申请号：US17618283

申请日：2020-06-09

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Simona GALLORINI ,  Federico NAPOLITANO ,  Alessandra VITELLI

IPC: A61K39/39 ,  A61K47/10 ,  A61K47/32 ,  A61K47/38 ,  A61P31/14

Abstract: Simian adenoviral vectors are formulated with bioadhesives and excipients that maintain immunogenicity. They can be administered mucosally to provide effective prophylaxis and therapy.

公开(公告)号：US20180256704A1

公开(公告)日：2018-09-13

申请号：US15800245

申请日：2017-11-01

Applicant: GlaxoSmithKline Biologicals, SA

Inventor： Alfredo NICOSIA ,  Ricardo CORTESE ,  Alessandra VITELLI

IPC: A61K39/155 ,  A61K39/275 ,  A61K39/235

Abstract: Administration regimens suitable for vaccine compositions comprising polynucleotides encoding immunogenic polypeptides. Such administration regimens involve the repeated administration of a vaccine composition.

公开(公告)号：US20240382583A1

公开(公告)日：2024-11-21

申请号：US18609504

申请日：2024-03-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Babak BAYAT ,  Clarisse LORIN ,  Ventzislav Bojidarov VASSILEV ,  Alessandra VITELLI

IPC: A61K39/29 ,  A61K39/00 ,  A61K39/39 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00

Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.